Clinical Core

临床核心

• 批准号: 10164695
• 负责人: JOHN MORRIS
• 金额: $ 68万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10164695
• 关键词: Address; Adult; African American; Age; Aliquot; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Amyloid; Amyloid beta-42; Area; Autopsy; Behavioral; Biological Assay; Biological Markers; Blood; Brain; Caring; Circadian Rhythms; Clinical; Clinical assessments; Cognitive; Communities; DNA; Data; Data Set; Dementia; Dermal; Development; Disease; Enrollment; Ensure; Etiology; Fibroblasts; Funding; Genetic; Glycosylated hemoglobin A; Grant; Heterogeneity; Image; Impaired cognition; Individual; Infrastructure; Life Cycle Stages; Liquid substance; Longitudinal Studies; Magnetic Resonance Imaging; Measures; Minority; Nature; Neurodegenerative Disorders; Neurologic; Neuropsychology; Nuclear Pore Complex; Participant; Plasma; Population; Population Heterogeneity; Positron-Emission Tomography; Procedures; Protocols documentation; Psychometrics; Research; Research Personnel; Research Priority; Research Project Grants; Resources; Risk; Sampling; Scientist; Severities; Sex Differences; Sleep; Structure; Third-Party Payer; Training; Vascular Dementia; aging brain; base; cognitive function; cognitive testing; cohort; data management; education research; imaging biomarker; induced pluripotent stem cell; informant; instrument; metropolitan; mild cognitive impairment; molecular phenotype; neuropathology; normal aging; novel; novel strategies; outreach; pre-clinical; programs; racial difference; recruit; repository; statistics; tau Proteins; tau-1; tool

Core B: Clinical Project Summary Core B: Clinical recruits, assesses, and follows all participants in the Knight ADRC Cohort. It uses well- established informant-based clinical and psychometric instruments (including the Uniform Data Set) at entry and annually thereafter to obtain clinical, cognitive, behavioral, and neurological data to carefully characterize each participant as to the presence or absence of dementia and, when present, its severity and etiology. The Core has successfully functioned to serve the needs of cutting-edge research projects of the Knight ADRC and its affiliated grants since its inception in 1985 and will continue to do so in the next 5-year funding period. The Core's Specific Aims in the proposed funding period are: 1. Maintain an current active cohort of participants (current N=272), carefully characterized as to the presence or absence of symptomatic AD, to support longitudinal studies of the clinical, cognitive, and biomedical correlates of symptomatic AD in comparison with cognitively normal aging and to mark the transition of participants with preclinical AD to cognitive impairment. 2. Annually enroll and assess 40 new participants age 65y or older (50y or older for symptomatic individuals), to replenish attritional losses and expand the active cohort to ~350. 3. Collect data, images, and biospecimens (DNA, CSF, plasma, dermal fibroblasts, and iPSCs) from participants as appropriate. 4. Solicit brain autopsy from all participants. 5. Continue to engage individuals in the African American community in St. Louis to promote the inclusion of African Americans in research. 6. In conjunction with the Research Education Component, use Core resources to train early stage investigators in dementia assessment, the heterogeneity of ADRD, and clinicopathological correlations that explore the multifactorial nature of AD. 7. Continue to ensure the broad sharing of Knight ADRC tools, data, and biospecimens and continue contributions to multicenter ADRD programs. 8. Address appropriate NAPA milestones related to cognitive data, longitudinal molecular phenotyping, sex and racial differences, sleep, and vascular contributions to dementia.

核心B：临床项目摘要 核心B：临床新兵，评估并跟随骑士ADRC队列中的所有参与者。它使用良好 既定的基于线人的临床和心理测量器（包括统一数据集） 此后每年获得临床，认知，行为和神经系统数据，以仔细表征 每个参与者的存在或不存在痴呆症以及其严重性和病因。这 Core已成功运作，以满足骑士ADRC和 自1985年成立以来，其附属赠款将在接下来的5年资金期间继续进行。这 Core在拟议的资金期间的具体目标是： 1。维持当前的主动参与者队列（电流n = 272），仔细地表征了存在 或没有症状AD，以支持临床，认知和生物医学的纵向研究 与认知正常衰老相比，有症状广告的相关性 具有临床前广告的参与者，涉及认知障碍。 2。每年注册并评估40名65岁或年龄以上的新参与者（有症状的人50岁或以上）， 补充损耗损失并将主动队列扩展到〜350。 3。从收集数据，图像和生物测量（DNA，CSF，血浆，皮肤成纤维细胞和IPSCS） 参与者适当。 4。征求所有参与者的脑尸检。 5。继续吸引圣路易斯非裔美国人社区的个人，以促进包含 非裔美国人研究。 6。与研究教育部分结合使用，使用核心资源来训练早期 痴呆评估的研究者，ADRD的异质性以及临床病理相关性 探索AD的多因素性质。 7。继续确保骑士ADRC工具，数据和生物测量的广泛共享，并继续 对多中心ADRD计划的贡献。 8。解决与认知数据，纵向分子表型，性别有关的适当的NAPA里程碑 以及种族差异，睡眠和对痴呆症的血管贡献。